Vanguard Global Advisers
CTXR icon

Vanguard Global Advisers’s Citius Pharmaceuticals CTXR Stock Holding History

Vanguard Global Advisers’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,788
Closed -$1.61K – 3666
2026
Q1 		$1.61K Buy
+1,788
New +$1.44K ﹤0.01% 3625

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Vanguard Global Advisers's CTXR Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Citius Pharmaceuticals (CTXR) in Q2 2026, closing a stake of 1,788 shares — an estimated $1.61K sold.

Vanguard Global Advisers first reported a position in CTXR in Q1 2026 and held it in 1 quarter. The position peaked at $1.61K in Q1 2026. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Citius Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 1,788 Citius Pharmaceuticals shares in Q2 2026, an estimated $1.61K.
  • Vanguard Global Advisers first reported a position in Citius Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Citius Pharmaceuticals position peaked at $1.61K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.